HeartMate-3 Ventricular Assist Devices Versus the Total Artificial Heart for Biventricular Support: A Single-Center Series
Mohan Satish, Anelechi Anyanwu, Noah Moss, Anuradha Lala, Shinobu Itagaki, Julie Roldan, Donna Mancini
Abstract
Introduction: The SynCardia total artificial heart (TAH) is the only device approved for biventricular support. Continuous flow ventricular assist devices (VAD) in a biventricular configuration (BiVAD) have been used with variable results. The purpose of this report was to examine differences in patient characteristics and outcomes between two HeartMate-3 (HM-3) VADs in comparison with TAH support.
Methods: All patients who received durable biventricular mechanical support from November 2018 to May 2022 at The Mount Sinai Hospital (New York) were considered. Baseline clinical, echocardiographic, hemodynamic, and outcome data were extracted. Primary outcomes were postoperative survival and successful bridge-to-transplant (BTT).
Results: A total of 16 patients received durable biventricular mechanical support during the study period, of which 6 (38%) patients received two HM-3 VAD pumps as BiVAD support and 10 (62%) patients received a TAH. Overall, TAH patients had a lower median lactate ( p < 0.05) at baseline compared to those on HM-3 BiVAD support yet had higher operative morbidity, lower 6-month survival ( p < 0.05), and a higher rate of renal failure (80 vs . 17%; p = 0.03). However, survival declined to the same rate at 1 year (50%) and was largely because of extracardiac adverse events related to underlying comorbidities (particularly, renal failure and diabetes, p < 0.05). Successful BTT was achieved in 3 out of 6 HM-3 BiVAD patients and in 5 out of 10 TAH patients.
Conclusion: In our single center experience, similar outcomes were observed among patients BTT with HM-3 BiVAD compared to those BTT on TAH support despite lower Interagency Registry for Mechanically Assisted Circulatory Support level.
Share
Publications
-
2-Year Clinical and Echocardiography Follow-Up of Transcatheter Mitral Valve Replacement With the Transapical Intrepid System
Vinayak Bapat, Eric Weiss, Sean Pinney, David H Adams, Angie Zhang , Michael Mack, Martin B Leon, et al. -
Optimal timing of Ross operation in children: A moving target?
Igor E Konstantinov, Emile Bacha, David Barron, Tirone David, Joseph Dearani, Yves d'Udekem, Ismail El-Hamamsy, Hani K Najm, Pedro J Del Nido, Christian Pizarro, Peter Skillington, Vaughn A Starnes, David Winlaw -
Mitral Valve Intervention in Elderly or High-Risk Patients: A Review of Current Surgical and Interventional Management
Maheedhar Gedela, Busra Cangut, Lucy Safi, Parasuram Krishnamoorthy, Dimosthenis Pandis, Ahmed El-Eshmawi, Gilbert H L Tang -
Total artificial heart implantation as a bridge to transplantation in the United States
Shinobu Itagaki, Nana Toyoda, Natalia Egorova, Erick Sun, Timothy Lee, Percy Boateng, Gregory Gibson, Noah Moss, Donna Mancini, David H Adams, Anelechi C Anyanwu